BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 29675840)

  • 1. Outcome of children with newly diagnosed acute lymphoblastic leukemia treated with CCLG-ALL 2008: The first nation-wide prospective multicenter study in China.
    Cui L; Li ZG; Chai YH; Yu J; Gao J; Zhu XF; Jin RM; Shi XD; Zhang LP; Gao YJ; Zhang RD; Zheng HY; Hu SY; Cui YH; Zhu YP; Zou Y; Ng MHL; Xiao Y; Li JH; Zhang YH; He HL; Xian Y; Wang TY; Li CK; Wu MY;
    Am J Hematol; 2018 Jul; 93(7):913-920. PubMed ID: 29675840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced intensity of early intensification does not increase the risk of relapse in children with standard risk acute lymphoblastic leukemia - a multi-centric clinical study of GD-2008-ALL protocol.
    Li XY; Li JQ; Luo XQ; Wu XD; Sun X; Xu HG; Li CG; Liu RY; Sun XF; Chen HQ; Lin YD; Li CK; Fang JP
    BMC Cancer; 2021 Jan; 21(1):59. PubMed ID: 33435902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
    Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
    Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of outcomes by early treatment responses in childhood T-cell acute lymphoblastic leukemia: a retrospective study in China.
    Wei W; Chen X; Zou Y; Chang L; An W; Wan Y; Liu T; Yang W; Chen Y; Guo Y; Zhu X
    BMC Pediatr; 2015 Jul; 15():80. PubMed ID: 26174476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
    Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
    Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.
    Bader P; Kreyenberg H; Henze GH; Eckert C; Reising M; Willasch A; Barth A; Borkhardt A; Peters C; Handgretinger R; Sykora KW; Holter W; Kabisch H; Klingebiel T; von Stackelberg A;
    J Clin Oncol; 2009 Jan; 27(3):377-84. PubMed ID: 19064980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Long-Term Outcome of 940 Children with Newly Diagnosed Acute Lymphoblastic Leukemia Treated with CCLG-ALL 2008: A Prospective Single Center Study in China].
    Zou Y; Chen XJ; Liu XM; Guo Y; Yang WY; Chen YM; Zhang L; Zhu XF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1075-1080. PubMed ID: 32798380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective evaluation of minimal residual disease as risk stratification for CCLG-ALL-2008 treatment protocol in pediatric B precursor acute lymphoblastic leukemia.
    Hu YX; Lu J; He HL; Wang Y; Li JQ; Xiao PF; Li J; Lv H; Sun YN; Fan JJ; Chai YH; Hu SY
    Eur Rev Med Pharmacol Sci; 2016 May; 20(9):1680-90. PubMed ID: 27212157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical Features and Prognosis of Acute T-cell Lymphoblastic Leukemia in Children--Multi-Center Data Analysis in Fujian].
    Wu CP; Zheng YZ; Li J; Wen H; Weng KZ; Zhuang SQ; Wu XG; Hua XL; Zheng H; Chen ZS; LE SH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):6-13. PubMed ID: 38387892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Interim results of a multicenter cohort study for Chinese Children Leukemia Group-acute lymphoblastic leukemia 2018 regimen].
    Chinese Children Leukemia Group
    Zhonghua Er Ke Za Zhi; 2023 Oct; 61(10):874-880. PubMed ID: 37803853
    [No Abstract]   [Full Text] [Related]  

  • 11. [Outcome of children with T cell acute lymphoblastic leukemia treated with Chinese Children Leukemia Group acute lymphoblastic leukemia (CCLG-ALL) 2008 protocol].
    Liu XM; Chen XJ; Zou Y; Wang SC; Wang M; Zhang L; Chen YM; Yang WY; Guo Y; Zhu XF
    Zhonghua Er Ke Za Zhi; 2019 Oct; 57(10):761-766. PubMed ID: 31594062
    [No Abstract]   [Full Text] [Related]  

  • 12. [Long-term outcome of childhood T-cell acute lymphoblastic leukemia treated with modified national protocol of childhood leukemia in China-acute lymphoblastic leukemia 2008].
    Liao C; Shen DY; Xu XJ; Xu WQ; Zhang JY; Song H; Yang SL; Zhao FY; Shen HP; Tang YM
    Zhonghua Er Ke Za Zhi; 2020 Sep; 58(9):758-763. PubMed ID: 32872717
    [No Abstract]   [Full Text] [Related]  

  • 13. [Evaluation of the efficacy of two successive protocols on pediatric acute lymphoblastic leukemia with E2A-PBX1 fusion gene].
    Mei YY; Gao C; Cui L; Zhao XX; Zhao W; Li WJ; Wang KL; Jiang J; Zhang RD; Xie J; Shi HW; Wang B; Zhang YH; Ma XL; Zhou X; Wu MY; Li ZG
    Zhonghua Er Ke Za Zhi; 2013 Jun; 51(6):467-71. PubMed ID: 24120066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group.
    Eckert C; Henze G; Seeger K; Hagedorn N; Mann G; Panzer-Grümayer R; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Schrauder A; Escherich G; Sramkova L; Niggli F; Hitzler J; von Stackelberg A
    J Clin Oncol; 2013 Jul; 31(21):2736-42. PubMed ID: 23775972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group.
    Pieters R; de Groot-Kruseman H; Van der Velden V; Fiocco M; van den Berg H; de Bont E; Egeler RM; Hoogerbrugge P; Kaspers G; Van der Schoot E; De Haas V; Van Dongen J
    J Clin Oncol; 2016 Aug; 34(22):2591-601. PubMed ID: 27269950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparison of the efficacy of two chemotherapy protocols for children with TEL-AML1[STBZ] fusion gene positive acute lymphoblastic leukemia].
    Wang KL; Mei YY; Cui L; Gao C; Liu FF; Zhao XX; Li WJ; Jiang J; Zhang RD; Xie J; Shi HW; Wang B; Zhang YH; Ma XL; Wu MY; Zhou X; Li ZG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):285-90. PubMed ID: 24762993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica.
    Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi AM; Messina C; Mori PG; Miniero R; Colella R; Basso G
    J Clin Oncol; 1995 Oct; 13(10):2497-502. PubMed ID: 7595699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study.
    Conter V; Bartram CR; Valsecchi MG; Schrauder A; Panzer-Grümayer R; Möricke A; Aricò M; Zimmermann M; Mann G; De Rossi G; Stanulla M; Locatelli F; Basso G; Niggli F; Barisone E; Henze G; Ludwig WD; Haas OA; Cazzaniga G; Koehler R; Silvestri D; Bradtke J; Parasole R; Beier R; van Dongen JJ; Biondi A; Schrappe M
    Blood; 2010 Apr; 115(16):3206-14. PubMed ID: 20154213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group.
    Biondi A; Valsecchi MG; Seriu T; D'Aniello E; Willemse MJ; Fasching K; Pannunzio A; Gadner H; Schrappe M; Kamps WA; Bartram CR; van Dongen JJ; Panzer-Grümayer ER
    Leukemia; 2000 Nov; 14(11):1939-43. PubMed ID: 11069029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial.
    Bader P; Kreyenberg H; von Stackelberg A; Eckert C; Salzmann-Manrique E; Meisel R; Poetschger U; Stachel D; Schrappe M; Alten J; Schrauder A; Schulz A; Lang P; Müller I; Albert MH; Willasch AM; Klingebiel TE; Peters C
    J Clin Oncol; 2015 Apr; 33(11):1275-84. PubMed ID: 25605857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.